Axon Enterprise, Inc $AXON Shares Acquired by Annis Gardner Whiting Capital Advisors LLC

Annis Gardner Whiting Capital Advisors LLC boosted its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 14,650.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,655 shares of the biotechnology company’s stock after buying an additional 2,637 shares during the period. Annis Gardner Whiting Capital Advisors LLC’s holdings in Axon Enterprise were worth $1,905,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter worth about $480,000. NewEdge Advisors LLC boosted its stake in Axon Enterprise by 41.1% during the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after purchasing an additional 668 shares during the period. Empowered Funds LLC grew its position in Axon Enterprise by 8.4% in the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after purchasing an additional 157 shares during the last quarter. Woodline Partners LP increased its stake in shares of Axon Enterprise by 40.6% in the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares during the period. Finally, Sivia Capital Partners LLC bought a new stake in shares of Axon Enterprise during the second quarter valued at approximately $284,000. 79.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent analyst reports. Morgan Stanley decreased their price objective on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. Barclays reduced their price target on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. UBS Group cut their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Finally, Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective for the company in a report on Tuesday, January 6th. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $805.71.

Axon Enterprise Trading Down 9.9%

Shares of Axon Enterprise stock opened at $549.86 on Thursday. The business has a fifty day simple moving average of $579.31 and a 200-day simple moving average of $672.62. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91. The firm has a market cap of $43.39 billion, a price-to-earnings ratio of 174.01, a price-to-earnings-growth ratio of 19.21 and a beta of 1.41. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. During the same period in the previous year, the firm earned $1.45 earnings per share. Axon Enterprise’s revenue was up 30.6% on a year-over-year basis. On average, equities analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, President Joshua Isner sold 20,000 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the completion of the sale, the president directly owned 249,502 shares of the company’s stock, valued at $137,874,805.20. This represents a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Jennifer H. Mak sold 1,134 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $600.00, for a total transaction of $680,400.00. Following the sale, the chief accounting officer owned 13,740 shares of the company’s stock, valued at $8,244,000. The trade was a 7.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 60,540 shares of company stock worth $34,684,738. Company insiders own 5.70% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.